Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. [electronic resource]
Producer: 20080527Description: 2350-7 p. digitalISSN:- 1527-7755
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- adverse effects
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Double-Blind Method
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Humans
- Lung Neoplasms -- drug therapy
- Middle Aged
- Protein Kinase Inhibitors -- adverse effects
- Quality of Life
- Quinazolines -- adverse effects
- Retrospective Studies
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.